Noncoding RNA therapeutics for substance use disorder

Abstract

Although noncoding RNAs (ncRNAs) have been shown to regulate maladaptive neuroadaptations that drive compulsive drug use, ncRNA-targeting therapeutics for substance use disorder (SUD) have yet to be clinically tested. Recent advances in RNA-based drugs have improved many therapeutic issues related to immune response, specificity, and delivery, leading to multiple successful clinical trials for other diseases. As the need for safe and effective treatments for SUD continues to grow, novel nucleic acid-based therapeutics represent an appealing approach to target ncRNA mechanisms in SUD. Here, we review ncRNA processes implicated in SUD, discuss recent therapeutic approaches for targeting ncRNAs, and highlight potential opportunities and challenges of ncRNA-targeting therapeutics for SUD.

Nanotechnology Lighting the Way for Gene Therapy in Ophthalmopathy: From Opportunities toward Applications

“…NADs include cDNA (translation function protein) [16], mRNA (translation function protein) [17] and noncoding RNAs [18]. Noncoding RNAs include ASO (antisense oligonucleic acid, binding target genes to regulate gene expression) [19], ribozymes (specific splicing RNA) [20], siRNA (RNA-induced silencing complexes (RISCs) degrade RNA) [21], miRNA (RISCs degrade RNA) [22], aptamers (specific binding to target molecules regulates gene expression) [23].…”